BI Asset Management Fondsmaeglerselskab A S Acquires 4,195 Shares of IQVIA Holdings Inc. (NYSE:IQV)

BI Asset Management Fondsmaeglerselskab A S grew its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 36.7% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 15,621 shares of the medical research company's stock after purchasing an additional 4,195 shares during the period. BI Asset Management Fondsmaeglerselskab A S's holdings in IQVIA were worth $3,614,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently made changes to their positions in the company. AdvisorNet Financial Inc lifted its stake in IQVIA by 327.6% during the fourth quarter. AdvisorNet Financial Inc now owns 124 shares of the medical research company's stock valued at $29,000 after buying an additional 95 shares in the last quarter. BKM Wealth Management LLC bought a new position in IQVIA during the fourth quarter valued at approximately $32,000. Activest Wealth Management bought a new position in IQVIA during the fourth quarter valued at approximately $35,000. CVA Family Office LLC bought a new position in IQVIA during the fourth quarter valued at approximately $43,000. Finally, CoreFirst Bank & Trust acquired a new position in IQVIA during the third quarter valued at approximately $44,000. Institutional investors own 89.62% of the company's stock.

IQVIA Stock Down 0.5 %

NYSE IQV traded down $1.09 during trading on Monday, hitting $230.09. The stock had a trading volume of 683,910 shares, compared to its average volume of 956,165. The company has a market capitalization of $41.92 billion, a PE ratio of 31.43, a P/E/G ratio of 2.32 and a beta of 1.52. The company's 50-day moving average price is $239.90 and its two-hundred day moving average price is $227.83. The company has a debt-to-equity ratio of 2.02, a quick ratio of 0.88 and a current ratio of 0.88. IQVIA Holdings Inc. has a 12 month low of $167.42 and a 12 month high of $261.73.

Insider Transactions at IQVIA

In other news, insider Kevin C. Knightly sold 8,607 shares of the company's stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $250.17, for a total transaction of $2,153,213.19. Following the sale, the insider now owns 5,251 shares in the company, valued at approximately $1,313,642.67. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other IQVIA news, insider Ari Bousbib sold 31,678 shares of the company's stock in a transaction on Friday, March 1st. The stock was sold at an average price of $250.53, for a total value of $7,936,289.34. Following the transaction, the insider now directly owns 796,752 shares of the company's stock, valued at approximately $199,610,278.56. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Kevin C. Knightly sold 8,607 shares of the company's stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $250.17, for a total value of $2,153,213.19. Following the completion of the transaction, the insider now directly owns 5,251 shares in the company, valued at $1,313,642.67. The disclosure for this sale can be found here. Company insiders own 1.60% of the company's stock.

Analyst Ratings Changes

IQV has been the topic of several research analyst reports. Robert W. Baird lowered their price objective on shares of IQVIA from $254.00 to $245.00 and set a "neutral" rating on the stock in a research note on Friday, May 3rd. SVB Leerink initiated coverage on IQVIA in a report on Monday, February 26th. They set an "outperform" rating and a $290.00 price objective for the company. Leerink Partnrs reaffirmed an "outperform" rating on shares of IQVIA in a report on Monday, February 26th. Guggenheim cut IQVIA from a "buy" rating to a "neutral" rating in a report on Thursday, February 15th. Finally, BTIG Research assumed coverage on IQVIA in a research report on Tuesday, February 13th. They issued a "buy" rating and a $285.00 price objective for the company. Three research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $257.57.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.